User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
The preparation of cellular monocyte-derived dendritic cell (Mo-DC) products for clinical settings comprises several independent processing steps including density gradient centrifugation, monocyte separation, cell culture (differentiation and maturation), and possibly electroporation. To meet the increasing regulatory requirements for cell-based therapeutics, we have integrated all manufacturing steps in a closed system operated by an automated cell processing instrument, the CliniMACS Prodigy® with CliniMACS® Electroporator.
Related PDFs:
CliniMACS® CD14 System (reference list)
Related products:
Recent reports suggest that simultaneous activation of different DC subsets may have a synergistic effect that can increase anti-tumor responses. We have established the idea of a new clinical approach based on primary DCs derived from peripheral blood using the CliniMACS Prodigy System. The CliniMACS Prodigy CD1c/CD304 Enrichment and Activation System enables fully automated production of BDC-based vaccines with high purities and recoveries.
Related products:
The CliniMACS® System in combination with our MACS® GMP Product Line offers a comprehensive portfolio optimized for the ex vivo GMP-compliant generation of DC vaccines.
Related products:
Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.
Download PDF
